Shanghai Taichu Biotechnology (Taichu Bio) recently welcomed Dr. Xiantang Li to its headquarters in Lingang, where he officially joins the company as a Senior Pathologist.

Dr. Xiantang Li

Dr. Li is an internationally renowned expert in toxicologic pathology and toxicology. He is a Diplomate of the American College of Veterinary Pathologists (DACVP) and a Diplomate of the American Board of Toxicology (DABT). He has extensive experience in teaching and research in experimental animal pathology, as well as in non-clinical safety research and management for pharmaceuticals. Before joining Taichu Bio, Dr. Li spent 24 years at Pfizer in non-clinical drug safety research. For over a decade, he served as Senior Director of Asia Operations within Pfizer's Non-Clinical Drug Safety R&D department, responsible for coordinating and overseeing non-clinical safety R&D and regulatory activities for Pfizer in China and the wider Asia-Pacific region (excluding Japan). Throughout his career, he has authored dozens of professional papers and contributed to more than 10 book chapters.

Taichu Bio's non-clinical safety research platform has established an organizational structure and operational departments in compliance with Good Laboratory Practice (GLP) requirements. The pathology research team is led by the esteemed toxicologic pathologist, Professor Lianshan Zhang (Ph.D. Supervisor), who serves as Head of the Pathology Research Department. Prof. Zhang holds leadership positions in several professional organizations, including Vice Chairwoman of the Pathology Committee of the Chinese Women Doctors Association, Standing Committee Member of the Pathology Committee of the Chinese Society of Toxicology, Standing Committee Member of the Pathology Committee of the Non-Governmental Medical Institutions Association of China, and Member of the Pathology Committee of the Chinese Pharmaceutical Association. She is also a member of the Japanese Society of Toxicologic Pathology. Under Prof. Zhang's leadership, Taichu Bio has developed a professional toxicologic pathology research team.

Dr. Li's addition will significantly enhance the overall quality and slide evaluation capabilities of Taichu Bio's pathology team. Furthermore, leveraging Dr. Li's extensive and long-standing experience in non-clinical safety R&D and toxicology research, his expertise will further strengthen the scientific and management standards of Taichu Bio's non-clinical research programs.